Denovo Biopharma

Executive Summary

Denovo Biopharma is a clinical-stage biopharmaceutical company pioneering a unique biomarker-driven drug development model. The company acquires late-stage drug candidates that have demonstrated safety but failed in broad Phase 2/3 trials, then uses its proprietary biomarker platform to identify genetic predictors of efficacy, thereby resurrecting these drugs for biomarker-selected patient populations. Focused on oncology and central nervous system (CNS) disorders, Denovo’s approach aims to increase the probability of success in later-stage trials by targeting patients most likely to respond. Founded in 2012 and headquartered in San Diego, the company operates as a private entity and has not disclosed total funding or valuation. Currently, Denovo is advancing a pipeline of repurposed assets, with lead programs in glioblastoma (CNS) and various solid tumors. The company’s biomarker-guided strategy has the potential to unlock value in previously abandoned assets, offering a cost-efficient path to approval. Key upcoming milestones include clinical data readouts from ongoing Phase 2 trials in biomarker-defined subgroups and potential partnership discussions to expand development. While specific financials are undisclosed, Denovo’s model has attracted attention for its ability to de-risk drug development, though execution risk remains given the reliance on biomarker validation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead CNS asset in biomarker-selected glioblastoma patients40% success
• Q4 2026Announcement of new partnership or licensing deal for oncology asset50% success
• H1 2027Initiation of Phase 3 trial for lead oncology program following positive Phase 2 results30% success